SEC Company Response from ORTHOPEDIATRICS CORP (KIDS) (CIK 0001425450) (KIDS) — Sep 28, 2017
ORTHOPEDIATRICS CORP (KIDS) (CIK 0001425450)
Date: Sept. 28, 2017 · CIK: 0001425450 · Accession: 0001571049-17-008039
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212076
Referenced dates: April 22, 2016, September 15, 2017
Letter
VIA EDGAR AND E-MAIL Office of Electronics and Machinery Securities and Exchange Commission Re: OrthoPediatrics Corp. Amendment No. 2 to Registration Statement on Form S-1 Filed September 8, 2017 File No. 333-212076
Dear Ms. Ravitz:
On behalf of OrthoPediatrics Corp. (the “Company”), attached for your review are revised pages to the Company’s Amendment No. 2 to the Registration Statement on Form S-1 (the “Registration Statement”) disclosing a reverse stock split, price range, share numbers and details regarding the Company’s incentive plan and offering-related restricted stock grants. These pages have been marked to reflect changes to Amendment No. 2 to the Registration Statement. A draft of the Company’s response (the “Response Letter”) to the comments of the Staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) relating to the Registration Statement is also attached. This submission is additionally being filed as correspondence through the Commission’s EDGAR system.
Any comments or questions regarding the foregoing should be directed to the undersigned at +1.312.876.7680. Thank you in advance for your cooperation in connection with this matter.
Very truly yours,
/s/ Christopher D. Lueking
Christopher D. Lueking, Esq.
of LATHAM & WATKINS LLP
cc: (via e-mail)
Mark C. Throdahl, OrthoPediatrics Corp.
Charles Ruck, Latham & Watkins LLP
Divakar Gupta, Cooley LLP
330 North Wabash Avenue
Suite 2800
Chicago, Illinois 60611
Tel: +1.312.876.7700 Fax: +1.312.993.9767
www.lw.com
FIRM / AFFILIATE OFFICES
Barcelona Moscow
Beijing Munich
Boston New York
Brussels Orange County
Century City Paris
Chicago Riyadh
[October 2], 2017
VIA EDGAR AND HAND DELIVERY
Amanda Ravitz
Assistant Director
Office of Electronics and Machinery
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Dubai Rome
Düsseldorf San Diego
Frankfurt San Francisco
Hamburg Seoul
Hong Kong Shanghai
Houston Silicon Valley
London Singapore
Los Angeles Tokyo
Madrid Washington, D.C.
Milan
Re: OrthoPediatrics Corp.
Amendment No. 2 to Registration Statement on Form S-1
Filed September 8, 2017
File No. 333-212076
Dear Ms. Ravitz:
On behalf of OrthoPediatrics Corp. (the “Company”), set forth below is the Company’s response to the comments of the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) relating to the Company’s Amendment No. 2 to the Registration Statement on Form S-1 (the “Registration Statement”). An electronic version of Amendment No. 3 to the Registration Statement (the “Amendment”) has been concurrently filed with the Commission through its EDGAR system. The enclosed copy of the Amendment has been marked to reflect changes made to the Registration Statement.
Set forth below is the Company’s response to the comment of the Staff’s letter to the Company, dated September 15, 2017, relating to the Registration Statement. For convenience of reference, the text of the Staff’s comment has been reproduced in bold and italics herein. The Company has provided its response immediately after the comment. Capitalized terms used but not otherwise defined herein have the meanings assigned to such terms in the Amendment.
Consolidated Statement of Operations, page F-4
1. We note the presentations of the foreign currency translation adjustment and comprehensive loss on page F-5 for the six months ended June 30, 2017. Revise the filing to provide a consolidated statement of comprehensive income as required by ASC 220-10-45.
Response: In response to the Staff’s comment, the Company has revised page F-5 of the Amendment to provide a consolidated statement of comprehensive loss for the six months ended June 30, 2017. Prior to the six months ended June 30, 2017, there were no transactions or activity required to be reported in other comprehensive loss/income.
[October 2], 2017
Page 2
Note 2. Significant Accounting Policies
Inventories, net page F-10
2. We note on page F-9 that you consign inventory to your customers. Please revise the filing to disclose the amount of consigned inventory held at each reporting period end as required by Question 2 paragraph 4 of SAB Topic 13A(2).
Response: In response to the Staff’s comment, the Company supplementally advises the Staff that its domestic inventory of implants and instruments, all of which is classified as finished goods, is held either in its warehouse or with independent sales agencies. Consistent with the guidance in SAB Topic 13(A)(2) and as disclosed on page 61 of the Amendment, the Company does not recognize domestic revenue upon shipment of inventory to the independent sales agencies, as title is still retained by the Company. Rather, domestic revenue is primarily recognized when the inventory is used by the hospital for surgeries, at which point title has passed to the respective hospital customer.
For international sales, title does in fact pass upon shipment to these international distributors. However, because the Company has concluded that collectability is not reasonably assured, international revenue is not recognized until cash has been received from the distributor in payment. Accordingly, the Company has separately disclosed inventory held by international distributors in the consolidated balance sheets on page F-3 of the Amendment.
The Company also respectfully refers the Staff to response No. 24 in its letter to the Staff, dated April 22, 2016, and notes that there has been no change to its inventory accounting policies since such date.
*********
Any comments or questions regarding the foregoing should be directed to the undersigned at +1.312.876.7680. Thank you in advance for your cooperation in connection with this matter.
Very truly yours,
Christopher D. Lueking, Esq.
Show Raw Text
CORRESP
1
filename1.htm
September 28, 2017
VIA EDGAR AND E-MAIL
Amanda Ravitz
Assistant Director
Office of Electronics and Machinery
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
330 North Wabash Avenue
Suite 2800
Chicago, Illinois 60611
Tel: +1.312.876.7700 Fax: +1.312.993.9767
www.lw.com
FIRM / AFFILIATE OFFICES
Barcelona
Moscow
Beijing
Munich
Boston
New York
Brussels
Orange County
Century City
Paris
Chicago
Riyadh
Dubai
Rome
Düsseldorf
San Diego
Frankfurt
San Francisco
Hamburg
Seoul
Hong Kong
Shanghai
Houston
Silicon Valley
London
Singapore
Los Angeles
Tokyo
Madrid
Washington, D.C.
Milan
Re: OrthoPediatrics Corp.
Amendment No. 2 to Registration Statement on Form
S-1
Filed September 8, 2017
File No. 333-212076
Dear Ms. Ravitz:
On behalf of OrthoPediatrics Corp.
(the “Company”), attached for your review are revised pages to the Company’s Amendment No. 2
to the Registration Statement on Form S-1 (the “Registration Statement”) disclosing a reverse stock
split, price range, share numbers and details regarding the Company’s incentive plan and offering-related restricted
stock grants. These pages have been marked to reflect changes to Amendment No. 2 to the Registration Statement. A draft of
the Company’s response (the “Response Letter”) to the comments of the Staff of the Division
of Corporation Finance of the Securities and Exchange Commission (the “Commission”) relating to the
Registration Statement is also attached. This submission is additionally being filed as correspondence through the
Commission’s EDGAR system.
Any comments or questions regarding the
foregoing should be directed to the undersigned at +1.312.876.7680. Thank you in advance for your cooperation in connection with
this matter.
Very truly yours,
/s/ Christopher D. Lueking
Christopher D. Lueking, Esq.
of LATHAM & WATKINS LLP
cc: (via e-mail)
Mark C. Throdahl, OrthoPediatrics Corp.
Charles Ruck, Latham & Watkins LLP
Divakar Gupta, Cooley LLP
330 North Wabash Avenue
Suite 2800
Chicago, Illinois 60611
Tel: +1.312.876.7700 Fax: +1.312.993.9767
www.lw.com
FIRM / AFFILIATE OFFICES
Barcelona
Moscow
Beijing
Munich
Boston
New York
Brussels
Orange County
Century City
Paris
Chicago
Riyadh
[October 2], 2017
VIA EDGAR AND HAND DELIVERY
Amanda Ravitz
Assistant Director
Office of Electronics and Machinery
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Dubai
Rome
Düsseldorf
San Diego
Frankfurt
San Francisco
Hamburg
Seoul
Hong Kong
Shanghai
Houston
Silicon Valley
London
Singapore
Los Angeles
Tokyo
Madrid
Washington, D.C.
Milan
Re: OrthoPediatrics Corp.
Amendment No. 2 to Registration Statement on Form
S-1
Filed September 8, 2017
File No. 333-212076
Dear Ms. Ravitz:
On behalf of OrthoPediatrics Corp. (the
“Company”), set forth below is the Company’s response to the comments of the Staff of the Division
of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”)
relating to the Company’s Amendment No. 2 to the Registration Statement on Form S-1 (the “Registration Statement”).
An electronic version of Amendment No. 3 to the Registration Statement (the “Amendment”) has been concurrently
filed with the Commission through its EDGAR system. The enclosed copy of the Amendment has been marked to reflect changes made
to the Registration Statement.
Set forth below is the Company’s response
to the comment of the Staff’s letter to the Company, dated September 15, 2017, relating to the Registration Statement. For
convenience of reference, the text of the Staff’s comment has been reproduced in bold and italics herein. The Company has
provided its response immediately after the comment. Capitalized terms used but not otherwise defined herein have the meanings
assigned to such terms in the Amendment.
Consolidated Statement
of Operations, page F-4
1. We note the presentations of the foreign currency translation adjustment and comprehensive loss on page F-5 for the six
months ended June 30, 2017. Revise the filing to provide a consolidated statement of comprehensive income as required by ASC 220-10-45.
Response: In response to
the Staff’s comment, the Company has revised page F-5 of the Amendment to provide a consolidated statement of comprehensive
loss for the six months ended June 30, 2017. Prior to the six months ended June 30, 2017, there were no transactions or activity
required to be reported in other comprehensive loss/income.
[October 2], 2017
Page 2
Note 2. Significant
Accounting Policies
Inventories,
net page F-10
2. We note on page F-9 that you consign inventory to your customers. Please revise the filing to disclose the amount of
consigned inventory held at each reporting period end as required by Question 2 paragraph 4 of SAB Topic 13A(2).
Response: In response to
the Staff’s comment, the Company supplementally advises the Staff that its domestic inventory of implants and instruments,
all of which is classified as finished goods, is held either in its warehouse or with independent sales agencies. Consistent with
the guidance in SAB Topic 13(A)(2) and as disclosed on page 61 of the Amendment, the Company does not recognize domestic revenue
upon shipment of inventory to the independent sales agencies, as title is still retained by the Company. Rather, domestic revenue
is primarily recognized when the inventory is used by the hospital for surgeries, at which point title has passed to the respective
hospital customer.
For international sales, title does
in fact pass upon shipment to these international distributors. However, because the Company has concluded that collectability
is not reasonably assured, international revenue is not recognized until cash has been received from the distributor in payment.
Accordingly, the Company has separately disclosed inventory held by international distributors in the consolidated balance sheets
on page F-3 of the Amendment.
The Company also respectfully refers
the Staff to response No. 24 in its letter to the Staff, dated April 22, 2016, and notes that there has been no change to its inventory
accounting policies since such date.
*********
Any comments or questions regarding the
foregoing should be directed to the undersigned at +1.312.876.7680. Thank you in advance for your cooperation in connection with
this matter.
Very truly yours,
Christopher D. Lueking, Esq.
of LATHAM & WATKINS LLP
Enclosures
[October 2], 2017
Page 3
cc: (via e-mail)
Mark C. Throdahl, OrthoPediatrics Corp.
Charles Ruck, Latham & Watkins LLP
Divakar Gupta, Cooley LLP